7th IPF Summit

FIbroGen’s recent Phase 3 trial failure for pamrevlumab exemplifies the critical time point the pulmonary fibrosis field is currently at as drug developers move through in-human to Phase 2 to Phase 3 trials to get the next disease-modifying drug to the patients in need.

The 7^th IPF Summit (September 19-21 | Boston) returns at this crucial stage for the drug development and academic communities to come together to address R&D bottlenecks, troubleshoot key discovery challenges, and share exclusive data to accelerate the latest ideas and innovations in the IPF field and supercharge a new era of IPF therapeutics.

If you haven’t yet seen the line-up of 42+ expert speakers, take a look at the full program in the event guide!

Are you looking to address and solve challenges with IPF therapeutic development, such as:  

1. Understanding cell cross-talk in the lung pathobiology of IPF, including epithelial and endothelial cells
2. Harnessing precision medicine for IPF including patient selectivity, combinational therapies, and biomarkers
3. Whether to incorporate imaging into your preclinical and clinical development and the potential of using imaging as an endpoint in IPF?

Then this is the event for you! This is your unique opportunity to leverage knowledge from world-leading IPF industry experts and KOL academics on the latest developments to overcome, discovery, preclinical, translational, and clinical, challenges of IPF therapeutic development for successful advancement of therapeutic candidates to in-human studies and beyond.

Join experts from the likes of Boehringer Ingelheim, Genentech, Pfizer, AstraZeneca, BMS, Pliant, Galecto, Vicore, Avalyn, Pieris, Moderna, Takeda and more who have already saved their places at the meeting.

See pricing and registration options here!